A co-crystal of regorafenib and pimelic acid and a preparation method thereof

Through the eutectics of regofenib and pimelic acid, the problem of insufficient water solubility and hygroscopicity of regofenib monohydrate was solved, and the effect of improving solubility and stability was achieved, laying the foundation for domestic replacement of imported products. .

CN111777552BActive Publication Date: 2024-11-19TIANJIN UNIVERSITY OF TECHNOLOGY
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202010707892.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-07-22
Publication Date
2024-11-19
Estimated Expiration
2040-07-22

AI Technical Summary

Technical Problem

The poor water solubility and high hygroscopicity of regolifenib monohydrate limit its application in preparations, and it is difficult to achieve domestic replacement of imported products, resulting in limited clinical application.

Method used

By eutectic screening with malonic acid, glutaric acid, pimelic acid, etc., the eutectics of regofenib and pimelic acid were successfully obtained. The X-ray powder diffraction pattern characteristic peaks measured by Cu Kα rays were used, and the preparation method was prepared It involves feeding regofenib and pimelic acid in a 1:1 molar ratio, adding solvent, stirring or grinding to obtain eutectics.

Benefits of technology

It significantly reduces the hygroscopicity of regolifenib, improves its solubility and stability, provides a basis for improving oral absorption, and simplifies the preparation process, which is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111777552B_ABST
    Figure CN111777552B_ABST
Patent Text Reader

Abstract

The present invention discloses a regorafenib and pimelic acid cocrystal and a preparation method thereof. The molar ratio of regorafenib to pimelic acid in the cocrystal is 1:1, and the X-ray powder diffraction pattern of the cocrystal has characteristic peaks at 2theta values ​​of 7.9±0.2°, 11.2±0.2°, 16.7±0.2°, 19.7±0.2°, and 24.1±0.2°. The cocrystal preparation method provided by the present invention has a simple process, an easy-to-control crystallization process, good reproducibility, and is suitable for industrial production. This cocrystal has lower hygroscopicity and higher apparent solubility than regorafenib monohydrate, which is beneficial to improving the stability and oral absorption efficiency of regorafenib.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical chemistry, and in particular to a regorafenib and pimelic acid cocrystal and a preparation method thereof. Background Art

[0002] Active pharmaceutical ingredients usually exist in crystalline forms, such as polymorphs, hydrates, solvates, salts and cocrystals. For the same active pharmaceutical ingredient, different crystalline forms have different physical and chemical properties. Therefore, in the pharmaceutical industry, it is of great significance to obtain suitable drug crystal forms. The existence of drugs in the form of cocrystals can improve the stability, solubility and processability of active pharmaceutical ingredients, which has significant advantages. Therefore, drug cocrystals are an effective means to improve the physical and chemical properties of active pharmaceutical ingredients.

[0003] The chemical name of Regorafenib is 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide, and its chemical structure is:

[0004]

[0005] Regorafenib is a new anticancer drug approved by the US FDA in September 2012 for the treatment of metastatic colorectal cancer. In February 2013, its new indication (advanced gastrointestinal stromal tumors) was approved through the FDA priority review process. Regorafenib is a new type of multi-kinase inhibitor that can block multiple enzymes that promote tumor growth. It was developed by Bayer and is marketed under the trade name Stivarga. The marketed form is the monohydrate of regorafenib free base. Patent CN101547903B discloses regorafenib monohydrate and its preparation method. However, regorafenib monohydrate has poor water solubility and certain hygroscopicity, which limits its application in preparations. In addition, the imported regorafenib listed in China is expensive, which is difficult for many patients to afford, further limiting its clinical application. Therefore, it is very necessary to find and develop a new crystalline form of regorafenib to improve its water solubility and hygroscopicity, reduce the threshold of preparation technology, and achieve domestic substitution for imports. The present inventors obtained a co-crystal of regorafenib and pimelic acid through a large number of co-crystal screenings, which can effectively improve the solubility and hygroscopicity of regorafenib. Summary of the invention

[0006] One of the objects of the present invention is to provide a co-crystal of regorafenib and pimelic acid; the second object of the present invention is to provide a method for preparing the co-crystal of regorafenib and pimelic acid; the third object of the present invention is to provide an application of the co-crystal of regorafenib and pimelic acid.

[0007] After a large number of experimental studies, the inventors tried to conduct co-crystal screening experiments with regorafenib and malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, etc., and finally successfully discovered the co-crystals of regorafenib with malonic acid, glutaric acid, pimelic acid, suberic acid, which can effectively reduce the hygroscopicity of regorafenib and improve the solubility of regorafenib, providing a material basis for improving the stability and oral absorption of regorafenib.

[0008] The technical solution adopted by the present invention is:

[0009] The present invention provides a cocrystal of regorafenib and pimelic acid.

[0010] A co-crystal of regorafenib and pimelic acid, the structural formula of the co-crystal is shown in formula (I):

[0011]

[0012] In this cocrystal, the molar ratio of regorafenib to pimelic acid is 1:1; the X-ray powder diffraction pattern of this cocrystal measured with Cu Kα rays has characteristic peaks at diffraction angles 2theta of 7.9±0.2°, 11.2±0.2°, 16.7±0.2°, 19.7±0.2°, and 24.1±0.2°.

[0013] Preferably, the X-ray powder diffraction pattern of the regorafenib and pimelic acid cocrystal measured with Cu Kα rays also has characteristic peaks at one or more of the diffraction angles 2theta of 8.9±0.2°, 10.7±0.2°, 12.7±0.2°, 15.9±0.2°, 22.4±0.2°, 22.6±0.2°, 23.1±0.2°, 25.1±0.2°, and 27.6±0.2°.

[0014] The present invention provides a method for preparing the regorafenib and pimelic acid cocrystal.

[0015] A method for preparing a cocrystal of regorafenib and pimelic acid comprises the following steps: adding regorafenib and pimelic acid at a molar ratio of 1:1, adding an appropriate amount of solvent, and then obtaining the cocrystal by stirring or grinding.

[0016] Preferably, in the preparation method of the cocrystal, the solvent is at least one of an alcohol solvent and an alkane solvent. The alcohol solvent includes but is not limited to methanol and ethanol; the alkane solvent includes but is not limited to n-heptane and dichloromethane; further preferably, the solvent is selected from one or more of methanol, ethanol, n-heptane and dichloromethane.

[0017] Preferably, in the method for preparing the cocrystal, the ratio of the total mass of regorafenib and pimelic acid to the amount of the solvent during stirring is 1 g: (2-28) mL; and the ratio of the total mass of regorafenib and pimelic acid to the amount of the solvent during grinding is 1 g: (100-200) μL.

[0018] In some preferred embodiments of the present invention, the method for preparing the co-crystal is specifically as follows: adding regorafenib and pimelic acid at a molar ratio of 1:1, adding a solvent, stirring, filtering, and drying the obtained solid product to obtain the co-crystal.

[0019] In some other preferred embodiments of the present invention, the method for preparing the co-crystal is specifically as follows: adding regorafenib and pimelic acid at a molar ratio of 1:1, adding a solvent and grinding to obtain the co-crystal.

[0020] In other preferred embodiments of the present invention, the method for preparing the co-crystal is specifically as follows: regorafenib and pimelic acid are added in a molar ratio of 1:1, the mixture is ground after adding a solvent, the obtained solid is added with a solvent and then stirred, filtered, and the obtained solid product is dried to obtain a co-crystal.

[0021] Preferably, in the method for preparing the cocrystal, the ratio of the total mass of regorafenib and pimelic acid to the amount of the solvent during stirring is 1 g: (2-28) mL.

[0022] Preferably, in the method for preparing the cocrystal, the ratio of the total mass of regorafenib and pimelic acid to the amount of the solvent used during grinding is 1 g: (100-200) μL.

[0023] The present invention provides a pharmaceutical composition, which comprises the cocrystal of regorafenib and pimelic acid and a pharmaceutically acceptable excipient.

[0024] In the present invention, pharmaceutically acceptable excipients refer to pharmaceutically acceptable materials, mixtures or solvents related to the consistency of the dosage form or pharmaceutical composition. Suitable pharmaceutically acceptable excipients will vary depending on the specific dosage form selected. In addition, pharmaceutically acceptable excipients can be selected according to their specific functions in the composition.

[0025] Preferably, pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, taste masking agents, colorants, anti-caking agents, humectants, chelating agents, plasticizers, viscosity enhancers, antioxidants, preservatives, stabilizers, surfactants and buffers.

[0026] The present invention also provides the use of the regorafenib and pimelic acid cocrystal in preparing a drug for preventing and / or treating cancer.

[0027] The beneficial effects of the present invention are:

[0028] The present invention converts regorafenib into a new cocrystal of regorafenib and pimelic acid for the first time. The cocrystal has lower hygroscopicity and higher apparent solubility than regorafenib monohydrate, which provides a material basis for improving the stability and oral absorption efficiency of regorafenib.

[0029] The preparation method of the regorafenib and pimelic acid cocrystal disclosed in the present invention has simple process, easy control of the crystallization process, good reproducibility, and is suitable for industrial production.

[0030] The regorafenib and pimelic acid cocrystal of the present invention has broad application prospects in preparing drugs for preventing and / or treating cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 is the X-ray powder diffraction pattern of the regorafenib and pimelic acid cocrystal prepared in Example 1;

[0032] Figure 2 is a differential scanning calorimetry analysis diagram of the regorafenib and pimelic acid cocrystal prepared in Example 1;

[0033] Figure 3 is a thermogravimetric analysis diagram of the regorafenib and pimelic acid cocrystal prepared in Example 1;

[0034] Figure 4 is the Fourier transform infrared spectrum of the regorafenib and pimelic acid cocrystal prepared in Example 1;

[0035] Figure 5 is the hydrogen nuclear magnetic resonance spectrum of the regorafenib and pimelic acid cocrystal prepared in Example 1;

[0036] Figure 6 is a dynamic moisture adsorption curve of the regorafenib and pimelic acid cocrystal and regorafenib monohydrate prepared in Example 1;

[0037] Figure 7 This is a powder dissolution curve of the regorafenib and pimelic acid cocrystal and regorafenib monohydrate prepared in Example 1. DETAILED DESCRIPTION

[0038] The present invention is further described in detail below by means of specific examples. Unless otherwise specified, the raw materials used in the examples can be obtained from conventional commercial sources.

[0039] Example 1

[0040] 1000 mg of regorafenib and 333 mg of pimelic acid were weighed and added to 20 mL of dichloromethane to obtain a suspension. The suspension was stirred at room temperature for 12 h, filtered, and the obtained white solid was dried at 40° C. to obtain a solid sample of regorafenib and pimelic acid cocrystal with a yield of 89.4%.

[0041] Example 2

[0042] Weigh 30 mg of regorafenib and 10 mg of pimelic acid, add into a ball mill, then add 5 μL of methanol, grind at 20 Hz for 60 min, add 1 mL of dichloromethane to obtain a suspension, stir the suspension at room temperature for 12 h, and dry the obtained white solid at 40°C to obtain a solid sample of regorafenib and pimelic acid cocrystal.

[0043] Example 3

[0044] Weigh 60 mg of regorafenib and 20 mg of pimelic acid, add 2 mL of n-heptane and 20 μL of ethanol to obtain a suspension, stir the suspension at room temperature for 24 h, filter, and dry the obtained white solid at 40° C. to obtain a solid sample of regorafenib and pimelic acid cocrystal.

[0045] Example 4

[0046] Weigh 60 mg of regorafenib and 20 mg of pimelic acid, add 2 mL of n-heptane and 20 μL of methanol to obtain a suspension, stir the suspension at room temperature for 12 h, filter, and dry the obtained white solid at 40° C. to obtain a solid sample of regorafenib and pimelic acid cocrystal.

[0047] Example 5

[0048] 30 mg of regorafenib and 10 mg of pimelic acid were weighed and added to a ball mill, and then 5 μL of methanol was added. The mixture was ground at a frequency of 20 Hz for 60 min. The obtained white solid was dried at 40° C. to obtain a solid sample of regorafenib and pimelic acid cocrystal.

[0049] Comparative Example

[0050] 1 g of regorafenib was weighed, and 10 mL of acetonitrile and 10 mL of water were added to obtain a suspension. The suspension was stirred at room temperature for 24 h, filtered, and the obtained white solid was dried at room temperature to obtain a solid sample of regorafenib monohydrate.

[0051] Characterization analysis

[0052] The present invention provides a regorafenib and pimelic acid cocrystal, which is characterized by X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis, Fourier transform infrared spectroscopy, nuclear magnetic resonance hydrogen spectroscopy and the like.

[0053] The solid sample of the regorafenib and pimelic acid cocrystal prepared in Example 1 was subjected to X-ray powder diffraction analysis using a Rigaku MiniFlex 600 diffractometer from Rigaku Co., Ltd., Japan, using Cu Kα radiation. The voltage was 40 kV, the current was 15 mA, the step length was 0.01°, the scanning speed was 20° / min, the scanning range was 5.0-40.0°, and the test temperature was room temperature. The analysis results are shown in the attached Figure 1 The X-ray powder diffraction pattern of , and the X-ray powder diffraction data are shown in Table 1.

[0054] Table 1 X-ray powder diffraction data of regorafenib and pimelic acid cocrystal of Example 1

[0055]

[0056]

[0057] Based on the same X-ray powder diffraction test method as in Example 1, the X-ray powder diffraction data of the solid sample of regorafenib and pimelic acid co-crystal prepared in Example 2 are shown in Table 2.

[0058] Table 2 X-ray powder diffraction data of regorafenib and pimelic acid cocrystal of Example 2

[0059]

[0060]

[0061] Based on the same X-ray powder diffraction test method as in Example 1, the X-ray powder diffraction data of the solid sample of regorafenib and pimelic acid co-crystal prepared in Example 3 are shown in Table 3.

[0062] Table 3 X-ray powder diffraction data of regorafenib and pimelic acid cocrystal of Example 3

[0063]

[0064]

[0065] It is well known to those skilled in the art that crystalline materials can be characterized by X-ray diffraction technology, but the X-ray diffraction pattern usually changes with the test conditions of the instrument. It is particularly important to point out that the relative intensity of the X-ray diffraction pattern may change with changes in experimental conditions, so the relative intensity order of the X-ray diffraction peaks cannot be used as the only or decisive factor in the characterization of crystalline materials. In addition, the peak angle is usually allowed to have an error of ± 0.2 °. Due to the influence of experimental factors such as sample height and test temperature, the overall shift of the peak angle will be caused, and a certain shift is usually allowed. Therefore, it can be understood by those skilled in the art that the X-ray diffraction pattern of the regorafenib and pimelic acid cocrystal described in the present invention does not have to be completely consistent with the X-ray diffraction pattern in this embodiment, and any situation with the same or similar characteristic peaks as in this spectrum belongs to the scope of the present invention. Those skilled in the art can compare the spectrum listed in the present invention with the spectrum of an unknown substance to confirm whether the unknown substance is or is not the regorafenib and pimelic acid cocrystal described in the present invention.

[0066] The solid sample of regorafenib and pimelic acid cocrystal prepared in Example 1 was subjected to differential scanning calorimetry analysis using a DSC 214 differential calorimeter manufactured by NETZSCH Scientific Instruments Co., Ltd., Germany, with a nitrogen atmosphere and a heating rate of 10°C / min. The analysis results are shown in the attached Figure 2 Differential scanning calorimetry analysis diagram of Figure 2 As shown, the cocrystal of regorafenib and pimelic acid exhibited endothermic peaks at 90 and 105 °C, suggesting that a crystal phase transition occurred, and a melting endothermic peak occurred at 149 °C.

[0067] The solid sample of regorafenib and pimelic acid cocrystal prepared in Example 1 was subjected to thermogravimetric analysis using a TG209 F3 thermogravimetric analyzer from NETZSCH Scientific Instruments Co., Ltd., Germany, with a nitrogen atmosphere and a heating rate of 10°C / min. The analysis results are shown in the attached Figure 3 Thermogravimetric analysis diagram of Figure 3 As shown, the cocrystal of regorafenib and pimelic acid begins to decompose when heated to around 150°C, and there is no weight loss before this temperature.

[0068] The regorafenib and pimelic acid cocrystal sample prepared in Example 1 was subjected to infrared spectroscopy analysis using a Vertex 70 Fourier transform infrared spectrometer from Bruker, Germany, with a detection range of 4000 to 500 cm -1 The analysis results are attached. Figure 4 Fourier transform infrared spectrum of Figure 4 It can be seen that the characteristic peak position of its infrared spectrum is (cm -1): 3377, 3352, 3296, 3209, 3145, 3111, 3072, 3028, 2981, 2947, 2594, 1760, 1710, 1635, 1591, 1542, 1485, 1407, 1326, 1305, 1267, 1224, 1195, 1164, 1126, 1029, 997, 966, 916, 894, 867, 823, 723, 680, 661, 570.

[0069] The regorafenib and pimelic acid cocrystal sample prepared in Example 1 was subjected to nuclear magnetic resonance hydrogen spectrum analysis using an Avance III 400M nuclear magnetic resonance spectrometer from Bruker, Germany. The analysis results are shown in the attached Figure 5 The H NMR spectrum of Figure 5 As can be seen, the peak of Regorafenib is: 1 H NMR (400MHz, DMSO-d6) δ9.53 (s, 1H), 8.81 (d, J = 4.8 Hz, 1H), 8.76 (s, 1H), 8.53 (d, J = 5.6 Hz, 1H), 8.20-8.10 (m, 2H), 7.68-7.58 (m, 2H), 7.41 (d, J = 2.5 Hz, 1H), 7.35 (dd, J = 11.6, 2.6 Hz, 1H), 7.19 (dd, J = 5.6, 2.6 Hz, 1H), 7.08 (d, J = 8.9 Hz, 1H), 2.78 (d, J = 4.8 Hz, 3H). The peaks of pimelic acid are: 1 H NMR (400 MHz, DMSO-d6) δ 12.01 (s, 2H), 2.18 (t, J = 7.3 Hz, 4H), 1.56-1.39 (m, 4H), 1.33-1.17 (m, 2H). According to the integration results of each peak, the stoichiometric ratio of regorafenib to pimelic acid in the cocrystal is 1:1.

[0070] Dynamic moisture sorption analysis

[0071] The dynamic water adsorption of regorafenib and pimelic acid cocrystal and regorafenib monohydrate powder samples was compared and analyzed.

[0072] Source of the tested samples: The co-crystal of regorafenib and pimelic acid was prepared by the method provided in Example 1 of the present invention; regorafenib monohydrate was prepared by the method provided in the comparative example of the present invention.

[0073] The powder samples of regorafenib and pimelic acid cocrystal and regorafenib monohydrate were ground and passed through 100 and 200 mesh sieves respectively to control the particle size between 75 and 150 μm. The DVS Intrinsic dynamic moisture adsorption instrument of SMS Company in the UK was used. The temperature was kept constant at 25°C. The system was kept in equilibrium under a nitrogen flow with a relative humidity of 0% until the mass remained unchanged. Then the relative humidity was controlled to run a cycle of 0%-95%-0% with a gradient of 10% to test the change of sample weight with humidity. The analysis results are attached. Figure 6 Dynamic moisture adsorption / desorption isotherms. Figure 6 It can be seen that regorafenib monohydrate is in dry equilibrium at a relative humidity of 0%. When the relative humidity rises to 10%, the moisture absorption and weight gain are 1.54%. When the relative humidity continues to rise to 95%, the quality remains stable without significant weight gain. When the relative humidity decreases, the moisture desorption curve and the adsorption curve basically coincide. In contrast, the hygroscopicity of regorafenib and pimelic acid cocrystal has been significantly improved. With the increase of relative humidity, regorafenib and pimelic acid cocrystal slowly absorb moisture and gain weight. When the relative humidity reaches 70%, the moisture absorption and weight gain are 0.06%. The relative humidity continues to rise, and the water absorption rate accelerates. When the relative humidity reaches 95%, the moisture absorption and weight gain are 0.20%. When the relative humidity decreases, the moisture desorption curve and the adsorption curve basically coincide.

[0074] Solubility evaluation

[0075] The powder dissolution data of regorafenib, pimelic acid cocrystal and regorafenib monohydrate were compared.

[0076] Source of the tested samples: The co-crystal of regorafenib and pimelic acid was prepared by the method provided in Example 1 of the present invention; regorafenib monohydrate was prepared by the method provided in the comparative example of the present invention.

[0077] Powder dissolution test method: grind the powder samples of regorafenib and pimelic acid cocrystal and regorafenib monohydrate, pass through 100 and 200 mesh sieves respectively, and control the particle size to 75-150μm. Weigh 21mg of regorafenib monohydrate and 26.6mg of regorafenib and pimelic acid cocrystal respectively, add them to 65mL of dissolution medium, take 0.5mL of solution at intervals, filter through 0.45μm microporous filter membrane, and dilute to an appropriate multiple, monitor the drug concentration at each time point by high performance liquid chromatography, and finally obtain the powder dissolution curve of each sample.

[0078] Powder dissolution conditions:

[0079] Dissolution medium: acetic acid-sodium acetate buffer solution, pH 4.5, containing 0.1% SDS;

[0080] Stirring speed: 150 rpm;

[0081] Dissolution temperature: 37±0.5℃;

[0082] Sampling time: 1, 2, 3, 5, 10, 30, 60, 120, 240 minutes;

[0083] Liquid phase conditions:

[0084] Instrument: SHIMADZU LC-2030C 3D;

[0085] Chromatographic column: Inertsil ODS C18 column (4.6 mm × 150 mm, 5 μm);

[0086] UV detection wavelength: 261nm;

[0087] Mobile phase: acetonitrile: aqueous solution containing 0.1% trifluoroacetic acid = 60:40;

[0088] Column temperature: 40°C;

[0089] Flow rate: 1 mL / min;

[0090] Injection volume: 20 μL.

[0091] The experimental results are attached. Figure 7 The powder dissolution curve of Figure 7 As shown in Figure 2, the maximum apparent solubility of regorafenib monohydrate and regorafenib and pimelic acid cocrystals were 0.28±0.034 and 5.74±0.14 μg / mL, respectively. It can be seen that the apparent solubility of regorafenib and pimelic acid cocrystals is unexpectedly significantly better than that of regorafenib monohydrate, reaching 20.5 times that of regorafenib monohydrate.

[0092] The regorafenib and pimelic acid cocrystal provided by the present invention can be used to prepare drugs for preventing and / or treating cancer, and has broad application prospects.

[0093] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A cocrystal of regorafenib and pimelic acid, characterized in that: The structural formula of the co-crystal is shown in formula (I): In the cocrystal, the molar ratio of regorafenib to pimelic acid is 1:1; the X-ray powder diffraction pattern of the cocrystal measured by Cu Kα rays has characteristic peaks at diffraction angles 2theta of 7.9±0.2°, 11.2±0.2°, 16.7±0.2°, 19.7±0.2°, and 24.1±0.2°.

2. The eutectic according to claim 1, characterized in that: The X-ray powder diffraction pattern of the co-crystal also has characteristic peaks at one or more of the diffraction angles 2theta of 8.9±0.2°, 10.7±0.2°, 12.7±0.2°, 15.9±0.2°, 22.4±0.2°, 22.6±0.2°, 23.1±0.2°, 25.1±0.2°, and 27.6±0.2°.

3. A method for preparing the eutectic according to any one of claims 1 to 2, characterized in that: The method comprises the following steps: adding regorafenib and pimelic acid in a molar ratio of 1:1, adding a proper amount of solvent, and then obtaining a cocrystal by stirring or grinding.

4. The preparation method according to claim 3, characterized in that: The solvent is at least one of an alcohol solvent and an alkane solvent.

5. The preparation method according to claim 3, characterized in that: During the stirring, the total mass of regorafenib and pimelic acid to the solvent is in the ratio of 1 g: (2-28) mL.

6. The preparation method according to claim 3, characterized in that: During the grinding, the total mass of regorafenib and pimelic acid to the solvent is 1 g: (100-200) μL.

7. A pharmaceutical composition, characterized in that: The invention comprises the co-crystal according to any one of claims 1 to 2 and a pharmaceutically acceptable excipient.

Citation Information

Patent Citations

  • 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate

    CN101547903B

  • Regorafenib salt, crystal thereof and preparation method of crystal

    CN103923001A

  • Crystal form of regorafenib salt and preparation method and application thereof

    CN104736521A

  • Regorafenib and wogonin eutectic and application thereof

    CN111116462A